<DOC>
	<DOCNO>NCT02771457</DOCNO>
	<brief_summary>The primary purpose project determine best schedule restart infliximab patient inflammatory bowel disease ( IBD ) specifically ulcerative colitis Crohn 's disease , undergone infliximab infusion . The primary endpoint would failure rate ; need discontinue infliximab change treatment . A secondary aim determine infliximab drug antibody level predict clinical outcome 1 year . Other secondary outcome include compare short-term long-term steroid free remission rate , serum fecal inflammatory marker response infliximab .</brief_summary>
	<brief_title>Managing Infliximab Reinduction After Temporary Discontinuation Drug</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects 18 year old willing able provide inform consent HIstory IBD ( Crohn 's disease , ulcerative colitis , indeterminate colitis ) standard clinical , histological , radiographic date . History stable clinical response prior IFX induction regular maintenance dosing , determine enrol clinician . Prior drug holiday , stable dose infliximab least 3 infusion regular maintenance interval Infliximab drug holiday least 12 week . Inability unwillingness provide inform consent Pregnant patient Prior history serious infusion reaction IFX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Influximab</keyword>
	<keyword>IFX</keyword>
	<keyword>Remicade</keyword>
</DOC>